dCTP焦磷酸酶1调节肿瘤细胞核苷酸代谢及表型的研究进展

基础医学与临床 ›› 2021, Vol. 41 ›› Issue (11): 1666-1670.

dCTP焦磷酸酶1调节肿瘤细胞核苷酸代谢及表型的研究进展

李婧, 张玫瑰, 白仲添^*

兰州大学第一临床医学院, 甘肃兰州 730000

收稿日期:2020-08-04 修回日期:2020-11-23 发布日期:2021-10-27
通讯作者: *baizht07@lzu.edu.cn
基金资助:
国家自然科学基金(81702326)

Research progress of dCTP pyrophosphatase 1 regulating nucleotide metabolism and phenotype of tumor cells

LI Jing, ZHANG Mei-gui, BAI Zhong-tian^*

The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China

Received:2020-08-04 Revised:2020-11-23 Published:2021-10-27
Contact: *baizht07@lzu.edu.cn

摘要/Abstract

摘要： 三磷酸脱氧胞苷焦磷酸酶1(dCTP焦磷酸酶1,DCTPP1)是新发现的靶向三磷酸脱氧胞苷(dCTP)的焦磷酸酶,它不仅通过水解常规性和修饰性dCTP调节胞嘧啶代谢,而且参与其他嘧啶核苷酸的稳态调节。肿瘤细胞进程中,DCTPP1的高表达有利于稳定脱氧核苷三磷酸池(dNTP池)的平衡和基因组的甲基化水平,维持肿瘤细胞基因组稳定性。此外,DCTPP1通过不同的信号途径促进肿瘤细胞的增殖、转移等恶性表型,并与肿瘤耐药及临床不良预后相关。DCTPP1或将成为抗肿瘤药物研发的“明星”靶点。对其调节机制的深入研究有望为肿瘤核苷酸代谢类靶向抑制剂研发提供新策略。

关键词: 三磷酸脱氧胞苷焦磷酸酶1(DCTPP1), 脱氧核苷三磷酸池(dNTP池), 核苷酸代谢, 抗肿瘤

Abstract: Deoxycytidine triphosphate pyrophosphatase 1(dCTP pyrophosphatase 1, DCTPP1) is a newly discovered pyrophosphatase targeting deoxycytidine triphosphate (dCTP). It regulates cytosine metabolism by not only hydrolyzing conventional and modified dCTP, but also participating in the steady-state regulation of other pyrimidine nucleotides. In the process of tumor cells, the high expression of DCTPP1 is facilitate to stabilize the balance of deoxynucleoside triphosphate pool (dNTP pool),methylation of the genome, and maintainance of stability of the tumor cell genome. Besides, DCTPP1 promotes malignant phenotypes such as tumor cell proliferation and metastasis through different signal pathways, and it is related to tumor drug resistance and poor clinical prognosis. DCTPP1 may become a “star” target for the development of anti-tumor drugs. In-depth research on its regulatory mechanism is expected to provide a new strategy for the development of targeted inhibitors of tumor nucleotide metabolism.

Key words: deoxycytidine triphosphate pyrophosphatase 1(DCTPP1), deoxynucleoside triphosphate pool(dNTP pool), nucleotide metabolism, antitumor

中图分类号:

R730.53

李婧, 张玫瑰, 白仲添. dCTP焦磷酸酶1调节肿瘤细胞核苷酸代谢及表型的研究进展[J]. 基础医学与临床, 2021, 41(11): 1666-1670.

LI Jing, ZHANG Mei-gui, BAI Zhong-tian. Research progress of dCTP pyrophosphatase 1 regulating nucleotide metabolism and phenotype of tumor cells[J]. Basic & Clinical Medicine, 2021, 41(11): 1666-1670.

参考文献

[1]Buj R, Aird KM. Deoxyribonucleotide triphosphate metabolism in cancer and metabolic disease[J]. Front Endocrinol (Lausanne), 2018, 9: 177, doi: 10.3389/fendo.2018.00177. eCollection 2018.
[2]Scaletti E, Claesson M, Helleday T, et al. The first structure of an active mammalian dCTPase and its complexes with substrate analogs and products[J]. J Mol Biol, 2020, 432: 1126-1142.
[3]Singh AK, Velumurugan A, Gupta DS, et al. Draft genome sequence of a less-known wild Vigna: beach pea (V. marina cv. ANBp-14-03)[J]. Crop J, 2019, 7: 660-666.
[4]Requena CE, Pérez-Moreno G, Ruiz-Pérez LM, et al. The NTP pyrophosphatase DCTPP1 contributes to the homoeostasis and cleansing of the dNTP pool in human cells[J]. Biochem J, 2014, 459: 171-180.
[5]Martínez-Arribas B, Requena CE, Pérez-Moreno G, et al. DCTPP1 prevents a mutator phenotype through the modulation of dCTP, dTTP and dUTP pools[J]. Cell Mol Life Sci, 2020, 77: 1645-1660.
[6]Zhang Y, Jia S, Song H, et al. Silencing DSCAM-AS1 suppresses the growth and invasion of ER-positive breast cancer cells by downregulating both DCTPP1 and QPRT[J]. Aging-Us, 2020, 12: 14754-14774.
[7]Lee EJ, Seo JH, Park JH, et al. SAMHD1 acetylation enhances its deoxynucleotide triphosphohydrolase activity and promotes cancer cell proliferation[J]. Oncotarget, 2017, 8: 68517-68529.
[8]Morisaki T, Yashiro M, Kakehashi A, et al. Comparative proteomics analysis of gastric cancer stem cells[J]. PLoS One, 2014, 9: e110736. doi:10.1371/journal.pone.0110736. eCollection 2014.
[9]Martinez-Arribas B, Requena CE, Perez-Moreno G, et al. DCTPP1 prevents a mutator phenotype through the modulation of dCTP, dTTP and dUTP pools[J]. Cell Mol Life Sci, 2020, 77: 1645-1660.
[10]Lu J, Dong W, He A, et al. Autophagy induced by overexpression of DCTPP1 promotes tumor progression and predicts poor clinical outcome in prostate cancer[J]. Int J Biol Macromol, 2018, 118: 599-609.
[11]叶永康, 米其武, 曾彦茹, 等. 过表达三磷酸胞嘧啶脱氧核苷酸焦磷酸酶1促进前列腺癌细胞株LNCaP细胞周期活动[J]. 中华实验外科杂志, 2018,35:2190-2192.
[12]Jordaens S, Cooksey L, Bonney S, et al. Serum profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia[J]. Br J Haematol, 2020, 189: 500-512.
[13]Wang H, Wang X, Xu L, et al. Prognostic significance of MYCN related genes in pediatric neuroblastoma: a study based on TARGET and GEO datasets[J]. BMC Pediatr, 2020, 20:314.doi:10.1186/s12887-020-02119-1.
[14]Zhang Y, Ye WY, Wang JQ, et al. dCTP pyrophosphohydrase exhibits nucleic accumulation in multiple carcinomas[J]. Eur J Histochem, 2013, 57:e29. doi: 10.4081/ejh.2013.e29.
[15]Friese A, Kapoor S, Schneidewind T, et al. Chemical genetics reveals a role of dctp pyrophosphatase 1 in Wnt signaling[J]. Angew Chem Int Ed Engl, 2019, 58: 13009-13013.
[16]Lu J, Dong W, He H, et al. Autophagy induced by overexpression of DCTPP1 promotes tumor progression and predicts poor clinical outcome in prostate cancer[J]. Int J Biol Macromol, 2018, 118(Pt A): 599-609.
[17]Tsesmetzis N, Paulin CBJ, Rudd SG, et al. Nucleobase and nucleoside analogues: resistance and re-sensitisation at the level of pharmacokinetics, pharmacodynamics and metabolism[J]. Cancers (Basel), 2018, 10:240. doi: 10.3390/cancers10070240.
[18]Requena CE, Perez-Moreno G, Horvath A, et al. The nucleotidohydrolases DCTPP1 and dUTPase are involved in the cellular response to decitabine[J]. Biochem J, 2016, 473: 2635-2643.
[19]Sarr A, Bre J, Mullen P, et al. Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031[J]. Sci Rep, 2019, 9:7643, doi: 10.1038/s41598-019-44089-3.
[20]Xia LL, Tang YB, Song FF, et al. DCTPP1 attenuates the sensitivity of human gastric cancer cells to 5-fluorour-acil by up-regulating MDR1 expression epigenetically[J]. Oncotarget, 2016, 7: 68623-68637.
[21]Noel P, Von Hoff DD, Saluja AK, et al. Triptolide and its derivatives as cancer therapies[J]. Trends Pharmacol Sci, 2019, 40: 327-341.
[22]Peters GJ, Sarkisjan D, El Hassouni B, et al. Unusual mechanism of resistance to the novel cytidine analog fluorocyclopentenylcytosine (RX-3117)[J]. Cancer Res, 2019, 79: 1267. doi: 10.1158/1538-7445.AM2019-1267.